Stockreport

Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting

Galectin Therapeutics Inc.  (GALT) 
Last galectin therapeutics inc. earnings: 11/12 08:00 am Check Earnings Report
PDF NORCROSS, Ga., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today a [Read more]